NCT00503971 2025-03-07
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Phase 1/2 Terminated
Clinical Trials
33 trialsNCT01413750 2024-11-12
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04190056 2023-08-31
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT00785798 2022-04-04
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Yale University
Phase 1/2 Terminated
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03050450 2021-04-05
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
Johns Hopkins All Children's Hospital
Phase 1 Terminated
NCT00324740 2021-02-23
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT02395627 2020-07-07
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
Phase 2 Terminated
NCT02589145 2019-12-13
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT00702962 2018-10-22
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT00958074 2018-10-18
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT00910000 2018-09-10
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00818649 2017-12-28
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01312818 2017-12-28
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01187446 2017-11-20
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Stanford University
Phase 1/2 Terminated
NCT00662311 2017-06-14
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
University of Washington
Phase 1/2 Terminated
NCT00673153 2017-06-01
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00948688 2017-05-10
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
Massachusetts General Hospital
Phase 1/2 Terminated
NCT01267240 2017-04-14
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00976183 2017-04-10
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Gynecologic Oncology Associates
Phase 1/2 Terminated
NCT00127101 2015-04-21
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00424775 2015-04-20
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00132002 2015-03-19
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00251589 2015-03-06
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00363883 2015-02-13
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01194427 2013-05-17
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00831493 2012-02-28
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated